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Pregnancy coordinately alters the contractile properties of
both vascular and uterine smooth muscles reducing systemic
blood pressure and maintaining uterine relaxation. The pre-
cise molecular mechanisms underlying these pregnancy-in-
duced adaptations have yet to be fully defined but are likely to
involve changes in the expression of proteins regulating myo-
sin phosphorylation. Here we show that smoothelin like pro-
tein 1 (SMTNL1) is a key factor governing sexual develop-
ment and pregnancy induced adaptations in smooth and
striated muscle. A primary target gene of SMTNL1 in these
muscles is myosin phosphatase-targeting subunit 1 (MYPT1).
Deletion of SMTNL1 increases expression of MYPT1 30–40-
fold in neonates and during development expression of both
SMTNL1 and MYPT1 increases over 20-fold. Pregnancy also
regulates SMTNL1 and MYPT1 expression, and deletion
SMTNL1 greatly exaggerates expression of MYPT1 in vascu-
lar smooth muscle, producing a profound reduction in force
development in response to phenylephrine as well as sensitiz-
ing the muscle to acetylcholine. We also show that MYPT1 is
expressed in Type2amuscle fibers inmice and humans and its
expression is regulated during pregnancy, suggesting unrec-
ognized roles in mediating skeletal muscle plasticity in both
species. Our findings define a new conserved pathway in
which sexual development and pregnancy mediate smooth
and striated muscle adaptations through SMTNL1 and
MYPT1.
Smooth and striated muscles show phenotypic plasticity in
response to physiological stresses such as exercise and preg-
nancy (1–5). Each phenotypic state is characterized by the
expression of a unique set of structural, contractile, and recep-
tor proteins that correlate with differing patterns of gene
expression (2, 6–10). Exercise-induced changes in muscle phe-
notype have been most extensively studied at the molecular
level in striated muscle, but is less well defined in smooth mus-
cles (2, 3, 11). Pregnancy promotes major changes in smooth
muscles throughout the body through the actions of the steroid
hormones 17-estradiol and progesterone (4, 12, 13). Both hor-
mones act by binding to their respective nuclear hormone
receptors (PR and ER), coordinately altering gene expression
patterns within their respective target tissues (14). For example
in uterine muscle during pregnancy, progesterone maintains
myometrial relaxation by directly inhibiting the expression of
estrogen-sensitive genes e.g. the oxytocin receptor (OXTR),
PGF2, C-43, and PGDH. Additionally, mesenteric and uterine
arteries regulating uterine blood flow, exhibit less vascular tone
and contractility (15). At parturition contractility of uterine
smooth muscle is restored by promoting expression of estro-
gen-regulated genes such as OXTR (16). Although less well
studied at the molecular level, vascular smooth muscle under-
goes substantial changes during pregnancy that are also
thought to be associated with remodeling. These adaptive
responses underlie reduced systemic blood pressure (BP)
thereby accommodating the increased cardiac out put and
blood volume associated with normal pregnancy (16–18). In
general vascular smooth muscle plasticity is beneficial, how-
ever, under pathological conditions it can also be detrimental.
Hypertension can cause blood vessels to become hypertrophic
causing blood flow resistance resulting in cardiac hypertrophy
(19). Preeclampsia and eclampsia are complications of preg-
nancy that are associated with persistent hypertension in
women.
The major mechanism governing the contractile activity of
all smooth muscles is the phosphorylation of the regulatory
light chain (MLC20) of myosin by calcium/calmodulin-depen-
dent myosin light chain kinase (MLCK), while relaxation is
effected by the dephosphorylation of MLC20 by myosin phos-
phatase (PP1M) (20, 21). Regulatory factors governing the
phosphorylation state of myosin are thought to be primary
determinants for promoting adaptive responses in smooth
muscles. The role phosphorylation and PP1M in the regulation
of striated muscle myosin is less well defined. Both smooth and
striated PP1M consist of a heterotrimer composed of the 37
kDa catalytic subunit of protein phosphatase 1 (PP1c), a 110–
130-kDamyosin-targeting subunit (MYPT)3 and a 20-kDa sub-
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unit of unknown function (20, 21). MYPT has three main iso-
forms, MYPT1, -2, and -3, which function to target PP1C to
myosin and regulate its phosphatase activity. MYPT1 is
expressed in smooth muscles, whereas MYPT2 and 3 are
expressed preferentially in heart, skeletal muscle (SKM), and
brain (22). Although the MYPT promoter lacks recognizable
transcription factor binding sites suggesting its expressionmay
not be regulated, isoform switching from MYPT1 to MYPT2
was observed in the differentiation of C2C12 cells from non-
muscle to skeletal muscle cells (23, 24). Additionally, develop-
mental switch ofMYPT1 isoforms caused a significant increase
in the rate of relaxation in the transition from the fetal to the
adult circulation in rat vascular smooth muscle (25). Fischer et
al. (15) recently reported expression of MYPT1 was increased
in uterine artery during normal pregnancy, and in a ratmodel of
hypertension in pregnancy, expression of C-terminal leucine
zipper splice variants ofMYPT1 (LZ and LZ) was regulated.
MYPT1 is also a target of several signaling pathways, including
G-protein-coupled receptors acting through Rho kinase and
NO/cGMP acting through PKG that positively and negatively
regulate PP1M to acutely control smooth muscle tone respec-
tively (20, 21).
A potential protein effector of PP1M is smoothelin-like
protein 1 (SMTNL1) (26–28). SMTNL1 contains a calponin
homology domain (CH2) at its C terminus while the remaining
two-thirds of the primary sequence is entirely uniquewithin the
mammalian databases (26, 29). Gene deletion studies in mice
demonstrated that SMTNL1 plays a role in cGMP/cAMP-me-
diated adaptations to exercise involving direct modulation of
contractile activity in vascular smooth muscle. Inhibition of
PP1M activity by SMTNL1 toward myosin and isolated light
chains in vitrowas also shown (27, 28). Additionally, in striated
muscle, SMTNL1 was found to be specifically expressed in
Type 2a adaptive fibers and gene deletion promoted increased
numbers of these fibers inmales, suggesting a role inmediating
both striatedmuscle as well as vascular plasticity in response to
physiological stresses such as exercise (28).
From studies with smtnl1/ mice we noted several sex-re-
lated differences involving the SMTNL1 role in mediating
adaptive responses in vascular and striated muscle (28). Vascu-
lar smooth muscle from sedentary and exercise-trained female
smtnl1/mice exhibited more significant changes in respon-
siveness to  and  adrenergic agonists than their male coun-
terparts. Exercise also induced more significant reduction of
SMTNL1 expression in females compared with males. Striated
muscle from male smtnl1/ mice showed a greater tendency
to switch to an oxidative phenotype. Collectively these findings
suggested a role for SMTNL1 in mediating both vascular and
striated muscle plasticity in response to the sex-related hor-
mones. To investigate this hypothesis here we examined the
function of SMTNL1 during sexual development and preg-
nancy in smtnl1/ mice. Our findings suggest that a major
mechanism by which development and pregnancy affect
smooth muscle contractility is via regulation of SMTNL1,
which in turn directly regulatesMYPT1 expression, desensitiz-
ing smooth muscle containing tissues to Ca2-mediated sig-
nals. Additionally we show a similar development and pregnan-
cy-induced role for SMTNL1 in the regulation of MYPT1
expression in in Type2a oxidative fibers of striatedmuscle from
mice and humans.
EXPERIMENTAL PROCEDURES
Mouse Colony Maintenance, Pregnancy, and Pseudopreg-
nancy Studies—Congenic 129 SvEv smtnl1/mousewere cre-
ated as described (28). All procedures involving mice were
approved byDukeUniversityAnimalCare andUseCommittee.
For pregnancy studies 6–8 weeks matured female mice in
estrus were selected by the appearance of their vagina (30) and
also with lavarge method (31). Female littermates caged
together presented synchronized estrus in 98% of cases.
Females in estrus were mated with adult males overnight and
then examined the following morning(s) for the presence of a
vaginal plug. This was designated as day 0 of pregnancy. For
pseudopregnancy studies adult, 7–8-week-old matured female
in estrus were mated by vasectomized males obtained from
Taconic. Males were vasectomized by ligation of the vas defer-
ens and produced no sperm. Vasectomized mice then were
mixed with females at a ratio of 1:2; females were observed for
vaginal plug formation, which was designated as day 0 of
pseudopregnancy.
Phosphatase Assays—Myosin phosphatase activity was assayed
using smooth muscle whole myosin from pig bladder as the sub-
strate as described (32).
Immunohistochemistry—Fiber typing of isopenthane-frozen
mouse frozen plantarus (PL) sections (8 m) by immunofluo-
rescent staining using anti-MHC2a and 2b (Developmental
Studies Hybridoma Bank, developed under the auspices of the
NICHD andmaintained by the University of Iowa, Department
of Biology, Iowa City) was performed as described (28, 33).
Anti-MYPT1 (provided by D. J. Hartshorne, University of Ari-
zona) and anti-SMTNL1 antibodies (Proteinrech Inc.) were
applied simultaneously. Human rectus abdominis (RA) sam-
ples of patients of hysterectomy (non-pregnant) or C-section-
ing (pregnant) and sections of aged matched healthy woman
(35–40 years) were treated similarly to mice. Procedures
involving humans were approved by the University and Medi-
cal Center Institutional Review Board at East Carolina Univer-
sity. Formalin-fixed mouse tissues were sectioned at 4 m.
Antigen unmasking with heat-induced epitope retrieval was
applied using citrate retrieval buffer and Background buster
(Innovex Biosc.) buffer were used to reduce background. The
same method was applied on formalin-fixed human thoracic
aorta sections. A representative set of images from n  4–7
experiments are shown in figures. The inset shows the images of
secondary antibody control.
Protein Analysis, Quantitative Western, and Quantitative
Western Blot Analysis and Far Western Blot Analysis—Tissue
sampleswere frozen in liquidN2 at the time of harvest, stored at
80 °C, and homogenized and applied for Western blot analy-
sis as described (28) using the indicated antibodies. For the
study of MLC20 phosphorylation MLC20 and MLC20 phos-
pho-Ser-19 (Upstate) antibodies were applied. Protein concen-
tration was determined by Bradford method. Bio-Rad gel doc
system was used for data analysis (34). Densitometry of the
blots was performed, and scans were analyzed by the Volume
Analyze feature of the Molecular Analyst Software (Bio-Rad)
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and Image J. The density of the protein of interest was normal-
ized to the density of GAPDH (Thermo Scien.) and tubulin
(Sigma) internal controls (run on the same gel) and plotted as
relative numbers. Far Western analysis was conducted as
described before (34) using 0.1 mg of each recombinant pro-
teins (PKA, AMPK, NT-SMTNL1, and GST-MYPT1) and for
overlay 10 nM of NF-SMTNL1 and GST-MYPT1. For control
experiments no proteins were applied but anti-Flag and anti-
GST (Sigma) antibodies were used for Western blotting.
Cell Culture, Immunocytochemistry, and Confocal Micros-
copy—HeLa andASMCcells were cultured andmaintained in a
humidified 37 °C incubator with 5% CO2. HeLa cells were
transfected by 1 g of pcDNA/SMTNL1 (NP_077192) and
pcDNA/SMTNL1T301A. Cells were treated with 10 M
8BrcAMP (cA) for 30 min and with 10 M isoproterenol (ISO)
for 10 min. Subcellular fractionation of control and treated
HeLa cells were conducted as described (34). HeLa, T47D, and
ASMC cells were cultured on coverslips and were serum-
starved for 12 h. After blocking primary antibodies specific for
SMTNL1, SMTNLS301, and MYPT1 were applied. Alexa Fluor
488 and 564 were used as secondary antibodies and DAPI
(Molecular Probes) staining was applied for nuclear staining.
Immunocytochemical and -histochemical images were imaged
on Zeiss LSM 510 confocal laser scanning microscope (Carl
Zeiss, Jena, Germany) using 85–100 nm pinholes. Individual
random fields were collected using Apochromat 40 or 63 1.4
oil DIC immersion objective lenses. Final images represents z
serial sections with an individual slice thickness of 0.8–1.2mm.
Images were processed using LSM 5 Examiner software pro-
grams (Carl Zeiss Microscope Systems) and reproduced using
image-editing software (Photoshop, Adobe Systems, CA).
RNA Isolation and Real-time RT-PCR—RNeasy Lipid Tis-
sue Mini kit (Qiagen) was used to isolate total RNA from the
uterus (n  3) of wild type and/or smtnl1/ of pregnant
and/or non-pregnant mice according to the manufacturer’s
protocol. 1 g of RNA was reverse transcribed to cDNA using
the iScript cDNA synthesis kit (Bio-Rad) according to theman-
ufacturer’s protocol. PCR amplification of MYPT-1 was per-
formed (in triplicates) in a total volume of 13 l and included 5
l of cDNA, 6.5 l of iQ SYBR Green Supermix (Bio-Rad), 0.2
mM of forward primer (5-AAAGCGACGGTCTACTGGAG-
3) and 0.2 mM of reverse primer (5-AACAGAATCCGTCT-
GCGTCT-3). 36B4 gene was used for the normalization of
amplification. PCR was performed on an iCycler (Bio-Rad)
according to the following cycling conditions: an initial cycle of
15 min at 95 °C, 45 cycles of 45 s at 95 °C, 15 s at 55 °C, and 15 s
at 72 °C, followed by a melt-curve analysis cycle with steps of
10 s each at 0.5 °C increments from 60 to 95 °C. Amplification
rates were visualized and analyzed on ICYCLER IQ optical sys-
tem software Version 3.0 (Bio-Rad).
Isometric Force Measurements—Descending thoracic aortas
were dissected, and aortic rings were dissected free of adjacent
tissues. Segments were cut for mounting in a wire myograph
and the passive stretch was set to 15 mNs to simulate the wall
tension generated by 100 mmHg of blood pressure. Dose-re-
sponse curves to phenylephrine (PE) and acetylcholine (Ach)
were determined as described (28).
Statistical Analysis—Tomake conclusions robust to individ-
ual variation in the studied variables among experimental ani-
mals, data were normalized by taking values obtained for WT
males as 1 and by calculating a corresponding proportional
value for WT females and both sexes of KO mice. Normalized
data were analyzed by Student’s t-tests (for two groups) or by
general linear models (GLM, for2 groups). Groups not con-
nected by the same letter are significantly different (p 0.05).
Parametric statistical tests were used if the assumptions of such
testsweremet. In other cases, we log-transformeddata for anal-
yses. In GLMs, we tested all possible interaction terms and
report here the final models obtained by excluding non-signif-
icant (p 0.05) interactions. When any covariate or factor was
significant in GLMs, we applied Tukey’s HSD procedure to test
for pair wise differences in groupmeans. GLMs andTukey tests
were conducted using the R statistical environment (R Devel-
opment Core Team 2008: A language and environment for sta-
tistical computing. R Foundation for Statistical Computing,
Vienna, Austria (ISBN 3-900051-07-0, version 2.8.1).
RESULTS
SMTNL1 Regulates the Expression of MYPT1 in Striated and
Smooth Muscle during Sexual Development—To understand
the role of SMTNL1 and its relationship with MYPT1 between
the sexes we first examined the expression of this phosphatase
subunit during early development in WT and smntl1/mice
(Fig. 1,A and B). InWT striated and smoothmuscle, MYPT1 is
expressed at low levels in neonates, but as the animals mature
sexually, expression increases 10–20-fold and the levels are
20–30% higher in developed males than females. Remarkably,
however, in both male and female smtnl1/ mice, MYPT1
expression shows a reciprocal age-dependent pattern of expres-
sion. MYPT1 expression in neonates is now 30–40-fold higher
than the levels found in WT littermates and exhibits a steady
decline as the animals become sexuallymature (Fig. 1,A andB).
In contrast, expression levels of the MYPT2 isoform was unaf-
fected by SMTNL1 deletion, suggesting that SMTNL1 specifi-
cally regulates MYPT1 expression. To investigate the relation-
ship between MYPT1 and SMTNL1, we examined the
expression of SMTNL1 throughout sexual development (Fig.
1C). Like MYPT1, SMTNL1 expression, increases in striated
muscle and also the difference in the level of expression
between males and females persists regardless of age. Similar
correlations between MYPT1 and SMTNL1 were observed
throughout development in thoracic aorta (Fig. 1, D and E).
To determine if increased expression of MYPT1 in response
to SMTNL1 deletion increases myosin phosphatase activity in
these tissueswemeasured PP1Mactivity following IPwith anti-
body to MYPT1 (Fig. 1F). Fig. 1F shows that the observed age-
dependent changes in the expression ofMYTP1 correlates with
increased total myosin phosphatase activity. This finding sug-
gests that increased expression of MYTP1 itself induces the
expression of the catalytic subunit of protein phosphatase 1
(PP1C). Our findings are consistent with recent work by Fro-
hman et al. (35) showing that MYPT1 and PP1c expression is
interdependent and knocking down of either subunit decreases
the expression level of the other subunit. Concomitant in-
creased expression of PP1C has also been observed following
SMTNL1 andMYPT1 in Pregnancy
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forced overexpression of MYPT2 using adenoviral vectors in
the heart (22).
MYPT1 Is Selectively Expressed inMouse andHumanType2a
Striated Fibers—The finding that development, as well as
SMTNL1 deletion induce expression of MYPT1 in striated
muscle is somewhat surprising since prior to our studies
MYPT2 has largely been reported as the major form of the
phosphatase subunit in this tissue (36). Previously we had
reported that in striated muscle SMTNL1 expression is
highly localized to Type2a fibers (28). Therefore given the
finding herein that SMTNL1 deletion promotes extraordi-
nary expression of MYPT1 in this muscle, we examined fiber
specific expression of the phosphatase subunit. Fig. 2 shows
remarkable discrete expression of MYPT1 in Type2a fibers
only, indicated by co-staining of SMTNL1 and MHC2a (Fig.
2A). Importantly, a similar staining pattern of MYPT1 and
SMTNL1 was also observed in Type 2a human abdominus
rectus striated muscle. As discussed, previous work showed
that SMTNL1 expression is also confined to Type2a fibers in
humans, suggesting that the relationship between this pro-
tein and MYPT1 is conserved across species (Fig. 2B). In
contrast, MYPT2 expression does not show muscle specific
fiber staining. To our knowledge, this is the first report
showing fiber-specific staining of MYPT1 in striated muscle
and suggests specific roles for the phosphatase in regulating
Type 2a fiber function.
Pregnancy Regulates the Expression ofMYPT1 in Striated and
SmoothMuscle inMice andHumans—Our observation of gen-
der related differences in both SMTNL1 and MYPT1 expres-
sion suggest unrecognized roles for these proteins inmediating
the actions of the sex related hormones. To explore this hypoth-
esis further we examined expression of both proteins during
pregnancy. Fig. 3A shows that during pregnancy SMTNL1
expression in striated muscle increases 2.5-fold by day 13 com-
pared with non-pregnant mice, and by 2-fold over levels
expressed inmales. Expression steadily declines through partu-
rition and the onset of lactation. Interestingly, expression of
SMTNL1 within all tissues examined mirrors that of serum
progesterone levels, which also peak at day 13–17 then declines
close to parturition. Pregnancy was also found to greatly induce
FIGURE 1.Development regulates the expression of SMTNL1 andMYPT1 in striated and vascular smoothmuscle. A and B, MYPT1 expression increases
in bothmale (A) and female (B)WTmice in striatedmuscle from the embryonic stage (E) andweek 1 to 8months (1w-8m), p 0.05.C, SMTNL1 expression from
embryonic stage (E) and ages 1week to 8months (1w-8m) frommale (M) and female soleus (SOL) muscle (D–E), relativeMYPT1 (D) and SMTNL1 (E) expression
in vascular smoothmuscle ofmales (M) and females (F) at age 5weeks. F, increased expressionofMYPT1 correlateswith increasedmyosin phosphatase activity
inmuscle extracts ofWT and smtnl1/ animals at 7 (black) and 21 (gray) days. Groups not connected by the same letter are significantly different, n 4	 S.E.,
GLM with Tukey-test, p 0.05.
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expression of SMTNL1 in vascular and uterine smooth muscle
by up to 10–12-fold (Fig. 3B).
Because SMTNL1 expression is regulated by exercise in stri-
ated muscle, two possible explanations may account for alter-
ations in the level of the protein in pregnant mice, either the
induction is related to the physical effects of increased weight
gain of the pregnant mother or SMTNL1 expression is hor-
monally regulated. To discriminate between these two possibil-
ities we examined SMTNL1 expression in pseudo-pregnant
mice. Pseudo-pregnant mice proceed with the normal hormo-
nal cycle observed in fully pregnant animals but do not experi-
ence weight gain from the developing fetal mice in utero. The
data in Fig. 3A show that SMTNL1 expression in pseudo-preg-
nant micemirrors that observed in fully pregnant animals, sug-
gesting that the expression changes aremore likely to be related
to changes in primary sex hormones present during normal
pregnancy, rather than as a result of physical stress arising from
the weight gain of the developing fetal mice.
Expression of MYPT1 was also found to closely mirror
SMTNL1 levels during pregnancy in all tissues examined (Fig.
3C). Fig. 3C shows that pregnancy promotes a 2–3-fold increase
in MYPT1 expression in striated, vascular, and uterine muscle.
By contrast, in smtnl1/ mice by day 13, MYPT1 expression
increased dramatically to 6–14 times over the levels observed
in pregnant WT littermates. Histological examination of
SMTNL1 and MYPT1 expression in plantarus muscle by con-
focal microscopy shows that pregnancy induces the expression
of both proteins within Type 2a fibers only, further confirming
a relationship between both proteins and this particularmuscle
fiber type (Fig. 3D). Deletion of SMTNL1 also greatly enhances
expression of MYPT1 within these fibers only. Immunohisto-
chemistry of non-pregnant uterus, showed SMTNL1 is ex-
pressed within myometrial cells of the uterus as well as in the
endometrial layer, and by day 13 of pregnancy expression is
increased dramatically in both cell types. Uterus contrasts with
aorta inwhich SMTNL1 expression is confined to smoothmus-
cle cells, with no significant staining in endothelial cells (Fig.
3D). As indicated in Western analysis, histological studies also
demonstrate that expression of SMTNL1 is also greatly induced
by pregnancy in aortal smooth muscle. The finding that
SMTNL1 is also discretely expressed within cells selectively
targeted by the primary sex hormones supports links between
the protein, MYPT1 and steroid hormone action. Quantitative
Western blotting of abdominus rectus muscles isolated from
age matched women undergoing either caesarean section
(C-section) or hysterectomy showed that bothMYPT1 and PP1
C expression are likely to be similarly regulated during preg-
nancy in humans. Fig. 3E shows that expression of MYPT1 is
induced2-fold by pregnancy with a similar concomitant fold
increase in PP1C expression. These findings indicate that the
mechanisms of regulation and functions of MYPT1 in striated
muscle are likely to be conserved across species.
To determine if the observed changes in MYPT1 at the pro-
tein level are due to transcriptional or post-transcriptional reg-
ulation we examined mRNA levels by RT-PCR in response to
pregnancy and SMTNl1 deletion. Supplemental Fig. S1 shows
that where as pregnancy promotes a 2 fold increase in MYPT1
mRNA suggesting hormone-mediated translational control,
SMTNL1 deletion alone has no effect on MYPT1 message lev-
els. MYPT1 message was increased to 2.5-fold in pregnant
smtnl1/ mice supporting the hypothesis that any effect
SMTNL1 has on MYPT1 mRNA synthesis requires additional
hormonal factors.
Collectively, at first glance our finding that both develop-
ment and pregnancy concomitantly increase SMTNL1 and
MYPT1 expression, as well increasing total endogenous PP1M
activity simultaneously, presents a paradox, since previous
work demonstrated that SMTNL1 inhibits PP1M activity in
vitro (28). In the discussion we suggest that this paradox can be
explained through regulation of SMTNl1 activity by phosphor-
ylation at Ser-301.
SMTNL1 Binds and Co-localizes with MYPT1 in Vivo—To
investigate whether SMTNL1 mediates its cellular effects
through direct interactions with MYPT1 we carried out co-IP
experiments from uterine and striated muscle isolated from
pregnantWT and smtnl1/mice (Fig. 4A). Fig. 4A shows that
IP with anti-SMTNL1 co-IPs MYPT1 and similarly SMTNL1
is co-IP with anti-MYPT1 antibody. The interactions are spe-
cific, because in control IP experiments with extracts from
smtnl1/ mice no MYPT1 is recovered with the SMTNL1
antibody (Fig. 4A). As observed in Western experiments, IP of
MYPT1 from striated and uterine muscle extracts prepared
SMTNL1
MHC2a
MYPT2
MYPT2
merge
merge
merge
merge
SMTNL1
MHC2a MYPT1
MYPT1
MHCIIb
MHCIIb MYPT2
MYPT1
Merge
Merge
A
B
FIGURE 2. Localization of MYPT1 in mouse and human striated muscle.
A, discrete expression of MYPT1 to Type2a fibers compared with MYPT2 in
plantarus (PL)muscle as determinedby co-stainingwithMHC2a andSMTNL1.
B, localization of MYPT1 and MYPT2 in Type2a and Type2b fibers in human
skeletal muscle by confocal microscopy. Scale bars represent 20 m.
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from smtnl1/mice resulted in recovery of a larger amount of
the protein than fromWTmice. Co localization ofMYPT1 and
SMTNL1 was also observed by immunofluorescent staining in
arterial smooth muscle cells showing diffuse cytosolic and dis-
crete nuclear localization for both
proteins (Fig. 4B). Interactions
between MYPT1 and SMTNL1
were also confirmed by far Western
analysis in which the purified re-
combinant forms of each protein
were found to recognize each other
in overlay experiments (supple-
mental Fig. S2). Although these
findings suggest direct interactions
between the two proteins, other
proteins may also participate to
facilitate binding in vivo.
Ser-301 Phosphorylation Regu-
lates Translocation of SMTNL1 to
the Nucleus—SMNTL1 is phos-
phorylated at Ser-301 in vivo in
response to agonists that elevate
intracellular cGMP or cAMP (27,
28). Our finding that SMTNL1 dele-
tion induces expression of MYPT1
in both smooth and striated muscle
tissues, and that this effect is greatly
exaggerated during pregnancy, sug-
gests a direct role for SMTNL1 in
the regulation of MYPT1 expres-
sion. Further, as shown in Western
blot experiments in Fig. 3, expres-
sion of both SMTNL1 and MYPT1
is highly reminiscent of the proges-
terone cycle during normal preg-
nancy, which also peaks between
day 13 and 17 in mice. To exert its
cellular effects progesterone binds
to its receptor (PR) in the cytosol
and translocates to the nucleus to
alter the transcriptional profile of
its target tissues. To determine if
SMTNL1 has the capacity to trans-
locate to the nucleus and impact
MYPT1 expression directly we
examined it subcellular location.
Fig. 5 shows that in vivo SMTNL1
localization is highly regulated and
phosphorylation at Ser-301 pro-
motes translocation of the protein
in both non-muscle as well as in-
tact muscle cells transfected with
SMTNL1. In its dephosphorylated
state, transfected WT SMTNL1
resides in the cytoplasm, but be-
comes highly localized within the
nucleus in response to 8-Br-cAMP
or isoproterenol (ISO) (Fig. 5A). In
contrast, mutation of Ser-301 to alanine blocks agonist depen-
dant nuclear localization of transfected FLAG-SMTNL1S301A
and is unresponsive to cAMP (Fig. 5A). Similar results were
observed following measurement of Ser-301 phosphorylation
FIGURE 3. Pregnancy regulates the expression of SMTNL1 and MYPT1 in striated and smooth muscle.
A, pregnancy and pseudopregnancy induce expression of SMTNL1 severalfold in striated muscle n 5	 S.E.
p  0.05. The inset below shows representative example of Western blot data. M, male expression levels.
B, pregnancy induces significant expression of SMTNL1 relative to plantarus muscle in vascular (aorta) and
uterine smooth muscle. Data shown are from day 0 and day 14 of pregnancy. Groups not connected by the
same letter are significantly different n  4 	 S.E., GLM with Tukey-test, p  0.01. The inset below shows
representative Western blots. C, pregnancy and SMTNL1 deletion induces MYPT1 expression in striated and
smooth muscles n 4	 S.E., p 0.05. The insets below show representative Western blots. D, upper panels
show black andwhite images of the effects of pregnancy onMYPT1 and SMTNL1 expression in Type 2a. Lower
panels show immunofluorescent images of SMTNL1 localization in uterus and aorta fromcontrol andpregnant
WT and smtnl1/mice by SMTNL1 (green). Images are a representative set of n 4 experiments. Scale bars
represent 20 m. E, MYPT1 and PP1C expression are induced in striated muscle from pregnant women under
going C-section compared non-pregnant women undergoing hysterectomy. Biopsy samples were taken from
the abdominus rectus muscles and processed for quantitative Western blot analysis with the indicated anti-
bodies, n 5	 S.E. p 0.05. Representative Western blots are shown below.
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using a phospho-Ser-301 specific antibody (Fig. 5B). To evalu-
ate whether SMTNL1 exhibits similar nuclear localization in
intact striated muscle, isolated soleus muscles were treated
with either ISO or 8BrcAMP (Fig. 5, C and D). Fig. 5, C and D
shows that both agonists elicit robust phosphorylation of Ser-
301 with concomitant recovery of SMTNL1 within the nuclear
fraction. The Ser-301 phosphorylation site resides C-terminal
to a putative nuclear localization sequence (NLS) 290KKDR293
suggesting a potential mechanism of regulation for SMTNL1
nuclear localization.
Increased Expression of MYPT1 in Pregnant smtnl1/Mice
Results in Profound Reduction in Isometric Force in Vascular
Smooth Muscle—To evaluate the effects of increased MYPT1
on smooth muscle contractile activity during pregnancy tho-
racic aorta was isolated from WT and smtnl1/ mice and
responsiveness to the contractile agonist Phe and relaxant Ach
was measured. Both agonists are known to affect myosin phos-
phorylation either through increasing intracellular Ca2
release (Phe) or by elevating intracellular cGMP through gen-
eration of endothelial nitric oxide (Ach). Fig. 6A shows that in
non-pregnant animals deletion of SMTNL1 promotes modest
desensitization to phenylephrine (WTPhe50% 1.2	 0.05M;
smtnl1/Phe50% 1.6	 0.03M n 5 S.E.). In bothWT type
and smtnl1/ mice, although pregnancy (day 13) had little
observable effect on sensitivity to phenylephrine (WT preg
Phe50%  1.5 	 0.04 M; smtnl1/ preg Phe50%  1.6 	 0.06
M n 5 S.E.), deletion of the protein had a profound effect on
maximal force (Fmax) development (WT preg Fmax  86 	 15
mN; smtnl1/ preg Fmax  35 	 9 mN n  5 S.E.) (Fig. 6B).
Measurement of the effects of acetylcholine to promote relax-
ation following maximal phenylephrine-induced contraction
showed that both pregnancy and SMTNL1 deletion had signif-
icant effects on responsiveness to the relaxant (Fig. 6,C andD).
Fig. 6C shows that SMTNL1 deletion has a sensitizing effect on
responsiveness to acetylcholine, increasing potency (WT
Ach50%  0.25 	 0.006 M n  7 S.E.; smtnl1/ Ach50% 
0.095	 0.002M n 6 S.E.) to the agonist as well as producing
greater extent of relaxation (Rmax) (WT Rmax  28 	 11 mN,
n 7; smtnl1/ Rmax 15	 8mN, n 6 S.E.). Fig. 6D shows
that pregnancy increases the relaxant effects of acetylcholine in
WT mice and that this effect is greatly exaggerated in
smtnl1/ mice (WT preg Ach50%  0.2 	 0.006 M, Rmax 
15	 4 mN, n 4 S.E.; smtnl1/ preg Ach50% 0.06	 0.001
M, Rmax 9.5	 3 mN, n 6 S.E.). The finding that both preg-
nancy and SMTNL1 deletion reduce force development in
response to phenylephrine and promote both the rate and
extent of relaxation in response to acetylcholine are consistent
withWestern blotting, immunohistochemical and biochemical
studies showing increased expression of MYPT1 in vascular
smooth muscle. Because acetylcholine is able to relax aorta
from smtnl1/ mice these findings suggest that SMTNL1 is
not essential for directly mediating all the actions of PKG in
vascular smooth muscle and that other targets of the protein
kinase remain intact. We and others have shown that several
proteins in addition to SMTNL1 participate in the regulation of
vascular smooth muscle relaxation including phosphorylation
ofMYPT1 at Ser-695, the intracellular Ca2 channel IRAG and
the PP1M inhibitor protein CP17 (21). However, examination
of basal phosphorylation levels of MLC20 using a phosphospe-
cific antibodies to Ser-19 does show both pregnancy and
SMTNL1 deletion promote endogenous myosin dephosphory-
lation (supplemental Fig. S3A). Furthermore, myosin phospha-
tase assays of extracts prepared fromWT and pregnant tissues
showed that both pregnancy and SMTNL1 deletion correlated
with an increase in total myosin phosphatase activity (sup-
plemental Fig. S3B). These results are consistent with the
induction of MYPT1 expression of observed in Western blot
and IHC experiments of aorta. Collectively our data suggest
FIGURE 4. SMTNL1 binds MYPT1 in striated and uterine smooth muscle.
A, SMTNL1 and MYPT1 were co-immunoprecipitated (IP) from uterus or
soleus extracts usingnon-immune serumas a control.B, cytosolic andnuclear
co-localization (merge, white) of endogenous SMTNL1 (green) and MYPT1
(red) in aortic smooth muscle cells. Scale bars, 10 m. elcihev
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FIGURE 5. SMTNL1 Ser-301 phosphorylation is required for translocation
to the nucleus. A, FT-SMTNL1 translocates to the nucleus followed by phos-
phorylation at Ser-301. HeLa cells were transfected with FT-SMTNL1 and
FT-SMTNL1S301A, treatedwith 10M8BrcAMP (cA) and 10M ISO, then immu-
nostained by antibody against Flag-tag (green scale bars, 10 m). B, endoge-
nous SMTNL1 is cytosolic but phosphor-Ser-301 SMTNL1 shows dominantly
nuclear subcellular localization in T47D cells. Scale bars, 10 m. C, SMTNL1 is
phosphorylated at Ser-301 in response to acute treatment of 10M 8BrcAMP
and ISO in different mammalian cell lines (HeLa cells are presented). n 4	
S.E. ***, p  0.001; **, p  0.01. D, subcellular distribution of SMTNL1 and
SMTNL1PS301. The subcellular fractions of HeLa cells as NUC (nucleus) andCYT
(cytosol, cytoskeleton) fractionswere analyzed. PGC-1 and tubulinwere used
as nuclear and cytosolic markers, respectively. Representative images are
shown, but similar results were obtained on separate occasions.
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that one of the major mechanisms by which pregnancy pro-
motes reduced systemic BP is by controlling MYPT1 expres-
sion levels in vascular smooth muscle to promote Ca2 desen-
sitization and myosin dephosphorylation. A key regulatory
factor in mediating these processes is SMTNL1.
DISCUSSION
In this report, we show that SMTNL1 plays a major role in
mediating adaptive responses in both smooth and striatedmuscle
during development and pregnancy supporting a role for the pro-
tein in mediating the actions of the major sex-related hormones.
Consistent with this hypothesis SMTNL1 deletion appears to
exaggerate the pregnant state in termsof the contractile responses
of isolated vascular smoothmuscle and effects onMYPT1 expres-
sion. The finding that pregnancy and SMTNL1 deletion greatly
increase the expression ofMYPT1 in vascular and uterine smooth
muscle now provide a molecular mechanism to explain preg-
nancy-induced relaxation in these tissues i.e. pregnancy promotes
MYPT1 expression increasingmyosin dephosphorylation, desen-
sitizing uterine and vascular smooth muscle to Ca2 signals,
thereby promoting uterine relaxation and reduced systemic BP.
The finding that increased MYPT1 expression correlates with
decreased basal levels of LC20 phosphorylation and increased
endogenousmyosin phosphatase activity support this conclusion.
Our data highlight the capacity of MYPT1 expression to be regu-
lated. During normal sexual development MYPT1 expression
increases 20-fold, in both males and females. Deletion of
SMTNL1 produces an extraordinary effect on basal expression in
neonates and sexually immature mice, increasing MYPT1 over
40-fold compared with WT litter mates. Prior to this study
MYPT1 has not been thought to have much capacity to be reg-
ulated at the protein level, largely due to an absence of recog-
nized transcription factor binding sites in its promoter region
(23). However, our studies examining MYPT1 mRNA levels by
real time PCR in response to pregnancy support recent findings
of Fischer et al. (15) in uterine artery showing both an increase
in MYPT1 expression at both the protein and message level,
suggesting that the protein is transcriptional regulated. In con-
trast, although SMTNL1 deletion alone induces large changes
in the expression of MYPT1 at the protein level in non-preg-
nant animals, we observed no direct effect on MYPT1 mRNA
levels (supplemental Fig. S1). These findings suggest that at the
protein level MYPT1 is likely to be regulated both transcrip-
tionally and post-transcriptionally and that SMTNL1 may play
a role at both levels. The finding that the expression of MYPT1
in greatly exaggerated in pregnant smntl1/ suggests that its
ability to regulateMYPT1 at the transcriptional level is likely to
be hormone dependent and indeed may act in a repressor
capacity, perhaps through interactions with the progesterone
or estrogen receptor. The finding that MYPT1 mRNA levels
were 25% higher in pregnant smtnl1/ animals compared
with pregnantWT litter mates supports this mechanism. Non-
hormone-dependent post-translational mechanisms of regula-
tion mediated through SMTNL1 could include roles in RNA
stability, translational regulation, protein stability or degrada-
tion. Sikorska and co-workers (37) recently demonstrated that
MYPT1 degradation has the capacity to be regulated in that the
Seven in absencia homolog 2 (SIAH2)-ubiquitin-proteosomal
pathways is responsible for the turnover of MYPT1. We are
currently investigating the effects of SMTNL1 deletion on
MYPT1 mRNA and protein turnover to investigate its role in
post-translation regulation of the phosphatase subunit. Impor-
tantly, alterations of expression of MYPT1 mediated by preg-
nancy also occurs in humans, with the finding that both
MYPT1 and PP1C are induced2-fold in Type2amuscle fibers
of abdominus rectus muscle taken from pregnant women
undergoing C-section compared with aged matched non-
pregnant women undergoing hysterectomy. The finding that
MYPT1 is also expressed selectively in Type 2a fibers in
humans also suggests that its functions are likely to be con-
served from mouse to humans.
Data showing increased expression ofMYPT1 in response to
SMTNL1 deletion and pregnancy present a paradox, because
pregnancy also induces expression of SMTNL1. This is further
complicated by previous findings showing that in vitro recom-
binant SMTNL1 inhibits PP1M activity toward myosin and
FIGURE 6. Increased expression of MYPT1 in pregnant smtnl1/ mice
promotes reduction in isometric force in response tophenylephrine and
sensitization toacetylcholine in isolated thoracic aorta.Measurements of
contractile activity were carried using the wire micrograph as described (36).
A, shows effects of SMTNL1 deletion on responsiveness to phenylephrine.
B, effects of pregnancy on the contractile response to phenylephrine in tho-
racic aorta isolated from pregnant WT and smtnl1/mice. In B, differences
were significant at 108 and 105 M Phe n 4–6,	 S.E. Student’s t test, p
0.0011. C, effects of SMTNL1 deletion on sensitivity to acetylcholine in non-
pregnant animals following treatment with 10 M phenylephrine. D, effects
of pregnancy on relaxation in response to acetylcholine inWT and smtnl1/
mice following precontractionwith 10Mphenylephrine. All points between
1 nM and 0.5 M were significant at p 0.001	 S.E.
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MLC20 (26, 28). Consequently one might expect that expres-
sion of SMTNL1 would be decreased, not increased by preg-
nancy if the protein directly regulates PP1M activity in vivo.
The finding that SMTNL1 activity and intracellular localization
are regulated by Ser-301 phosphorylation offers a mechanism
to explain this paradox. In previous work we had shown that
agonists that elevate intracellular cAMP or cGMP promote
phosphorylation of Ser-301 in vivo, and phosphorylation of this
amino acid inhibits the ability of SMTNL1 to inhibit PP1M in
vitro (27, 28). Herein we now show that phosphorylation Ser-
301 also promotes translocation of SMTNL1 to the nucleus.
We therefore hypothesize that SMTNL1 is a signal transduc-
tionmolecule acting as part of a feedbackmechanism to enable
cellular signals to regulate both the activity and expression of
MYPT1 and consequently PP1M activity (Fig. 7). In non-preg-
nant tissue SMTNL1 remains in the cytosol and suppresses
PP1M activity through interactions with MYPT1. In response
to adrenergic signaling Ser-301 becomes phosphorylated and
SMTNL1 translocates to the nucleuswhere itmay interact with
factors governing the expression MYPT1. As discussed, Ser-
301 resides N-terminal to a NLS sequence, therefore, could be
transported to the nucleus through interactions with import-
ins. Alternatively the protein could interact with the nuclear
hormone receptors targeted by progesterone or estrogen,
which in the absence of these hormones, also reside the cyto-
plasm, but translocate to the nucleus when bound to these ste-
roids. Because progesterone is recognized as the major hor-
mone governing pregnancy, a likely candidate for interaction
with SMTNL1 is the progesterone receptor (PR). If SMTNL1
interacts with PR this would provide a mechanism for the pro-
tein to not only alter MYPT1 expression at the gene level, but
also be involved coordinating wider gene responses related to
promoting smooth and striatedmuscle adaptations in response
to pregnancy. Such a mechanism of action may imply that in
females the default function for
SMTNL1 in non-pregnant animals
is to repress sex hormone function
from promoting pregnancy-like
adaptive responses in both vascular
smooth muscle and other tissues.
Under this scenario pregnancywould
therefore relieve SMTNL1 inhibition
of PR for example to promote appro-
priate adaptive responses such as the
increased expression of MYPT1 in
uterine and vascular smooth muscles
aswell as adaptations in striatedmus-
cles. Intriguingly, PKA-mediated sig-
naling pathways have long been
known to greatly effect progesterone
signaling in vivo, synergizing with the
hormone (38–41). In summary, loss
of SMTNL1 function deregulates
pathways that are normally sup-
pressed in non-pregnant animals,
therefore explaining the smtnl1/
phenotype in female mice.
The finding thatMYPT1 is exclu-
sively expressed in Type2a fibers from bothWT and smtnl1/
mice as well as human striated muscle was unexpected. Cur-
rently, the precise function of MYPT1 expression in Type2a
fibers can only be inferred from studies in vascular smooth
muscle showing that increased expression of the protein pro-
motes profound Ca2 desensitization and muscle relaxation.
However, the fiber specific localization of MYPT1 in Type2a
fibers suggests a re-evaluation of myosin phosphatase function
in regulating contractile activity in striatedmuscle iswarranted.
Prior to data presented herein, MYPT2 has been defined as the
major isoformofmyosin phosphatase subunit expressed in stri-
atedmuscle (22, 36). In early in vitro studiesMYPT2was shown
to exhibit a preference for striated muscle myosin over smooth
muscle isoforms. However, reports reporting the specificity of
both MYPT1 and MYPT2 isoforms for striated muscle myosin
were performed onmixedmyosins isolated fromwhole skeletal
muscle (36). The isolation of purified forms of native MHC2a
from MHC1 and MHC2b from the relevant striated muscle
types in sufficient quantities for biochemical studies is techni-
cally challenging. Based on our finding of selective localization
of MYPT1 in Type2a fibers only, we now suggest that when
complexed with PP1C, the subunit is likely to show selectivity
toward MHC2a over the other forms of striated muscle myo-
sins. Sequence alignments of the 3 major isoforms of striated
muscle MHC shows MHC2a shares 91% identity with MHC2b
and 94% identity with MHC I, whereas MHC2b and MHC1
share 94% identity, suggesting that MHC2a is more divergent
from the other isoforms. Indeed, the majority of the sequence
divergence occurs in the motor and hinge regions of MHC2a
(42). Additionally, there is considerably more sequence diver-
gence between the types of myosin light chain isoforms
expressed in striated fibers. The MLC20s, or slow twitch myo-
sin regulatory light chain, shares 52% sequence similarity
with the fast twitch MLC20f forms (42, 43). Both types are
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FIGURE 7. SMTNL1 regulates MYPT1 expression in pregnancy. In non-pregnant tissue SMTNL1 remains in
the cytosol and suppresses PP1Mactivity through interactionswithMYPT1. In response to phosphorylation by
PKA/PKC at Ser-301 SMTNL1 releasesMYPT1 and enters the nucleuswhere itmay interact with factors govern-
ing the expression MYPT1. During pregnancy SMTNL1 may also enter the nucleus where it may interact with
factors that also regulate MYPT1 expression such as the nuclear hormone receptors targeted by estrogen or
progesterone. This coordinated response adapts the mother’s physiological state to support the developing
fetus. Increased expression of MYPT1 in uterine and vascular smoothmuscle promotes myosin dephosphory-
lation and muscle relaxation. (R: receptor, S: steroid hormone).
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phosphorylated in vivo and are thought to sensitize striated
muscle to Ca2 to increase shortening velocity. Furthermore,
recent evidence suggests that striated muscle remodeling can
promote switching of individual light chains between MHC
forms (43).
To summarize, we have shown that SMTNL1 functions to
regulate MYPT1 expression in both smooth as well as striated
muscles. Further, both proteins are regulated during sexual
development and pregnancy and form a module that adapts
these tissues to alter their contractile properties. In smooth
muscle these pregnancy-induced adaptations most likely con-
tribute to reduced systemic blood pressure and uterine relax-
ation that occurs during normal pregnancy. In striated muscle
the role of both proteins has yet to be fully defined, but their
co-expression in Type2a adaptive fibers only strongly suggest a
previously unrecognized role in mediating pregnancy induced
alterations in striated muscle function.
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